Srinivas V. Kaveri

Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

D. Klatzmann, S. Kaveri, M. Kazatchkine, 1994, Therapeutic immunology.

Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro

N. Gupta, S. Kaveri, S. Lacroix-Desmazes, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A

N. Gupta, S. Kaveri, S. Lacroix-Desmazes, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.

S. Kaveri, S. Lacroix-Desmazes, J. Dimitrov, 2014, Blood.

Predictive immunogenicity of Refacto® AF

S. Kaveri, S. Lacroix-Desmazes, J. Dimitrov, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene

S. Kaveri, S. Lacroix-Desmazes, J. Oldenburg, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.